Testosterone implant therapy: efficacy and safety in transmen and native men with hypogondism

2014 ◽  
Author(s):  
Ye Kyaw ◽  
Maricel Espina ◽  
Leighton Seal
Keyword(s):  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
Implant Therapy

scholarly journals Ezetimibe-Statin Combination Therapy: Efficacy and Safety as Compared With Statin Monotherapy

2016 ◽  
Author(s):  
Barbara Nußbaumer ◽  
Anna Glechner ◽  
Angela Kaminski-Hartenthaler ◽  
Peter Mahlknecht ◽  
Gerald Gartlehner
Keyword(s):  
Combination Therapy ◽  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
Statin Monotherapy

Scrambler therapy efficacy and safety for neuropathic pain correlated with chemotherapy-induced peripheral neuropathy in adolescents: A preliminary study

2018 ◽  
Vol 65 (7) ◽  
pp. e27064 ◽  
Author(s):  
Caterina Tomasello ◽  
Rita Maria Pinto ◽  
Chiara Mennini ◽  
Elena Conicella ◽  
Francesca Stoppa ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
Scrambler Therapy ◽  
Preliminary Study

Long-term Exposure to Telmisartan as Monotherapy or Combination Therapy: Efficacy and Safety

2002 ◽  
Vol 11 (3) ◽  
pp. 173-181 ◽  
Author(s):  
Frank Freytag ◽  
Nicolaas J. Holwerda ◽  
Bengt E. Karlberg ◽  
Thomas W. Meinicke ◽  
Helmut Schumacher
Keyword(s):  
Combination Therapy ◽  
Efficacy And Safety ◽  
Therapy Efficacy

scholarly journals Phage Therapy in Veterinary Medicine

Antibiotics ◽  
2021 ◽  
Vol 10 (4) ◽  
pp. 421
Author(s):  
Rosa Loponte ◽  
Ugo Pagnini ◽  
Giuseppe Iovane ◽  
Giuseppe Pisanelli
Keyword(s):  
Phage Therapy ◽  
Farm Animals ◽  
Economic Losses ◽  
Bacterial Disease ◽  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
The Past ◽  
Treatment And Prevention

To overcome the obstacle of antimicrobial resistance, researchers are investigating the use of phage therapy as an alternative and/or supplementation to antibiotics to treat and prevent infections both in humans and in animals. In the first part of this review, we describe the unique biological characteristics of bacteriophages and the crucial aspects influencing the success of phage therapy. However, despite their efficacy and safety, there is still no specific legislation that regulates their use. In the second part of this review, we describe the comprehensive research done in the past and recent years to address the use of phage therapy for the treatment and prevention of bacterial disease affecting domestic animals as an alternative to antibiotic treatments. While in farm animals, phage therapy efficacy perspectives have been widely studied in vitro and in vivo, especially for zoonoses and diseases linked to economic losses (such as mastitis), in pets, studies are still few and rather recent.

How do CYP2C19*2 and CYP2C19*17 genetic polymorphisms affect the efficacy and safety of diazepam in patients with alcohol withdrawal syndrome?

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Valentin Yu Skryabin ◽  
Mikhail S. Zastrozhin ◽  
Marco V. Torrado ◽  
Elena A. Grishina ◽  
Kristina A. Ryzhikova ◽  
...  
Keyword(s):  
Genetic Polymorphisms ◽  
Alcohol Withdrawal ◽  
Withdrawal Syndrome ◽  
Safety Assessment ◽  
Alcohol Withdrawal Syndrome ◽  
Efficacy And Safety ◽  
Psychometric Scales ◽  
Therapy Efficacy ◽  
Scale Scores ◽  
Male Patients

Abstract Background Diazepam is one of the most commonly prescribed tranquilizers for therapy of alcohol withdrawal syndrome (AWS). Despite its popularity, there is currently no precise information on the effect of genetic polymorphisms on its efficacy and safety. The objective of our study was to investigate the effect of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy and safety of diazepam in patients with AWS. Methods The study was conducted on 30 Russian male patients suffering from the AWS who received diazepam in injections at a dosage of 30.0 mg/day for 5 days. The efficacy and safety assessment was performed using psychometric scales and scales for assessing the severity of adverse drug reactions. Results Based on the results of the study, we revealed the differences in the efficacy of therapy in patients with different CYP2C19 681G>A (CYP2C19*2, rs4244285) genotypes: (CYP2C19*1/*1) −8.5 [−15.0; −5.0], (CYP2C19*1/*2 and CYP2C19*2/*2) −12.0 [−13.0; −9.0], p = 0.021. The UKU scale scores, which were used to evaluate the safety of therapy, were also different: (CYP2C19*1/*1) 7.0 [6.0; 12.0], (CYP2C19*1/*2 and CYP2C19*2/*2) 9.5 [8.0; 11.0], p = 0.009. Patients carrying different CYP2C19 –806C>T (CYP2C19*17, rs12248560) genotypes also demonstrated differences in therapy efficacy and safety rates. Conclusions Thus, the effects of CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the efficacy of diazepam were demonstrated.

scholarly journals Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study

2020 ◽  
Vol 19 (6) ◽  
pp. 531-537
Author(s):  
Nikolay N. Murashkin ◽  
Eduard T. Ambarchian ◽  
Roman V. Epishev ◽  
Alexander I. Materikin ◽  
Leonid A. Opryatin ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Dermatology Life Quality Index ◽  
Pediatric Patients ◽  
Biological Therapy ◽  
Life Quality ◽  
Alternative Methods ◽  
Efficacy And Safety ◽  
Therapy Efficacy ◽  
Definition Of

Background. The study of psoriasis biological therapy aspects in children has certain topicality due to the small number and disunity of individual observations and the lack of special registers for pediatric patients.Objective. Our aim was to study ustekinumab efficacy and safety in children with plaque (PP), erythrodermic (EP) and palmoplanar (PPP) forms of psoriasis.Methods. The analysis of ustekinumab efficacy and safety has been carrying out for 1 year. The evaluation of therapy efficacy was based on definition of improvement of PASI scores (PASI 75, PASI 90 and PASI 100) on the 16th, 28th, 40th and 52nd weeks of follow-up and children's dermatology life quality index (CDLQI). Ustekinumab therapy safety analysis was based on registration and evaluation of adverse effects. Results. The study included 67 children with PP, EP and PPP aged 12 to 18 years. PP group results: the PASI 75 response at the 52nd week of therapy was observed in 35 children (100%), PASI 90 — in 33 (94%), PASI 100 — in 30 (86%). EP group results: 10 patients (56%) have reached PASI 75 on the 16th week, while none of patients have improved to PASI 90 and PASI 100 scores. The PASI 75 response at the 52nd week of therapy was observed in 18 children (100%), PASI 90 — in 17 (94%), PASI 100 — in 7 (39%). Only 1 patient (7%) with PPP has showed the score decrease to PASI 75 on the 16th week. Adverse effects were reported in 2 patients.Conclusion. Ustekinumab is the effective and safe treatment for moderate and severe forms of PP and EP in children, and it can also be considered as one of the alternative methods for PPP treatment in pediatrics.

scholarly journals Efficacy and Safety Outcomes of Intravitreal Dexamethasone Implant Therapy for the Treatment of Adult Coats’ Disease

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Qingshan Chen ◽  
Saying Liang ◽  
Xizhen Wang ◽  
Chenli Hu ◽  
Jieting She ◽  
...  
Keyword(s):  
Dexamethasone Implant ◽  
Efficacy And Safety ◽  
Intravitreal Dexamethasone Implant ◽  
Significant Difference ◽  
Safety Outcomes ◽  
Implant Therapy ◽  
Coats Disease ◽  
The Mean ◽  
Intravitreal Dexamethasone

Purpose. To evaluate the efficacy and safety outcomes of dexamethasone intravitreal implant in patients with Stage 3A Coats’ disease. Methods. A consecutive case series of adult Coats’ disease managed with or without intravitreal dexamethasone implant (Ozurdex®, Allergan Inc., Irvine, California, USA) injection was retrospectively evaluated. The medical records of all included patients with a minimum follow-up of 6 months were reviewed. The patients were divided into two groups according to the application of dexamethasone implant as a DEX (+) group and DEX (−) group. Laser photocoagulation, anti-VEGF agents, and vitrectomy were performed if necessary. The primary outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP) at month 6. Resolution of the exudative retinal detachment (ERD), subretinal fluid (SRF), and vitreous hemorrhage (VH) was also collected. Results. Ten eyes (10 patients) with Stage 3A Coats’ disease were included, and the mean follow-up time was 9.70 ± 4.42 months. The mean age was 44.20 ± 7.42 years, and 80% were male. Six eyes (6 patients) received intravitreal injection of Ozurdex were included in the DEX (+) group, while the other 4 eyes in the DEX (−) group. No significant difference of baseline characteristics including BCVA, CRT, IOP, and follow-up time can be defined between DEX (+) and DEX (−) groups. For the patients in the DEX (+) group, a significant improvement of BCVA was observed from the baseline of 1.28 ± 0.58 to 0.84 ± 0.66 logMAR at month 6 (P=0.03), while the CRT decreased from 970.33 ± 696.49 to 421.00 ± 275.76 μm (P=0.067). For the DEX(−) group, BCVA changed from 0.76 ± 0.74 to 0.96 ± 0.60 logMAR at month 6 (P=0.066), while the CRT from 382.75 ± 17.68 to 412.75 ± 195.53 μm (P=0.525) with no significant difference. IOP was elevated from 13.15 ± 1.74 mmHg at baseline to 18.05 ± 3.57 mmHg at month 6 with a P value of 0.02 for the DEX(+) group and from 14.48 ± 1.70 to 18.83 ± 4.06 mmHg (P=0.076) for the DEX (−) group. After a mean follow-up of 9.70 months, 5/6 (83.3%) eyes in the DEX (+) group and ¼ (25%) eye in the DEX (−) group achieved reattachment of ERD. Conclusion. Intravitreal dexamethasone implant therapy is effective for adult Stage 3A Coats’ disease, which provides a new treatment option for ophthalmologists.

Sign in / Sign up

Export Citation Format

Share Document